UPDATE 1-Roche's SMA drug trial win bolsters $2 bln sales prospects
January 23, 2020 at 03:32 AM EST
Roche's spinal muscular atrophy (SMA) drug risdiplam hit another clinical trial target, the Swiss drugmaker said on Thursday, which analysts said bolsters its prospects of reaching $2 billion in annual sales.